Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ganzinelli, Monica ^a   Rulli, Eliana ^b   Caiola, Elisa ^b   Chiara Garassino, Marina ^a   Broggini, Massimo ^b   Copreni, Elena ^b   Piva, Sheila ^c   Longo, Flavia ^d   Labianca, Roberto ^e   Bareggi, Claudia ^f   Agnese Fabbri, Maria ^g   Martelli, Olga ^h   Fagnani, Daniele ⁱ   Cristina Locatelli, Maria ^j   Bertolini, Alessandro ^k   Valmadre, Giuseppe ^l   Pavese, Ida ^m   Calcagno, Anna ⁿ   Giuseppa Sarobba, Maria ^o   Marabese, Mirko ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g BELCOLLE HOSPITAL   (Italy)

^h SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

ⁱ Medicina II   (Italy)

^j SAN CARLO BORROMEO HOSPITAL   (Italy)

^k Transfusion Medicine and Haematology Department   (Italy)

^l Azienda Ospedaliera Valtellina e Valchiavenna   (Italy)

^m FATEBENEFRATELLI HOSPITAL   (Italy)

ⁿ Legnano Hospital   (Italy)

^o UNIVERSITY HOSPITAL OF SASSARI   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; DOCETAXEL; ERLOTINIB; MICRORNA; RAS PROTEIN; TAXOID;

3' UNTRANSLATED REGION; AGED; ALLELE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; AGED; ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RAS PROTEINS; TAXOIDS;

EID: 84947272509     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16331     Document Type: Article

References (24)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Sato, M., Shames, D. S., Gazdar, A. F. & Minna, J. D. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2, 327-343 (2007).
3. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung Cancer. New England Journal of Medicine 359, 1367-1380 (2008).
4. Riely, G. J., Marks, J. & Pao, W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6, 201-205 (2009).
5. Chin, L. J. et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68, 8535-8540 (2008).
6. Paranjape, T. et al. A 3′ -untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12, 377-386 (2011).
7. Christensen, B. C. et al. A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30, 1003-1007 (2009).
8. Smits, K. M. et al. A Let-7 MicroRNA SNP in the KRAS 3′ UTR Is Prognostic in Early-Stage Colorectal Cancer. Clin Cancer Res 17, 7723-7731 (2011).
9. Caiola, E. et al. KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am J Cancer Res 2, 298-308 (2012).
10. Pharoah, P. D. et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 17, 3742-3750 (2011).
11. Ratner, E. S. et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 31, 4559-4566 (2011).
12. Nelson, H. H. et al. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 69, 51-53 (2010).
13. Rulli, E. et al. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol, (2015). doi: 10.1093/annonc/mdv318.
14. Garassino, M. C. et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14, 981-988 (2013).
15. Mascaux, C. et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92, 131-139 (2005).
16. Linardou, H. et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology 9, 962-972 (2008).
17. Ying, M., Zhu, X., Chen, K., Sha, Z. & Chen, L. Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. J Cancer Res Clin Oncol, (2015). doi: 10.1007/s00432-015-1910-9.
18. Piva, S. et al. Across the universe of k-ras mutations in non-small-cell-lung cancer. Curr Pharm Des 20, 3933-3943 (2014).
19. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005).
20. Lee, Y. S. & Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21, 1025-1030 (2007).
21. Reinhart, B. J. et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901-906 (2000).
22. Johnson, C. D. et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67, 7713-7722 (2007).
23. Kumar, M. S. et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105, 3903-3908 (2008).
24. Takamizawa, J. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64, 3753-3756 (2004).